Table 1

Characteristics of study patients
Age (years), median (range) 60.0 (20.0–80.0)
Sex (male/female) (%) 245 (47.5)/ 271 (52.5)
Body weight (kg), median (range) 58.0 (36.35–107.6)
BMI, median (range) 22.7 (15.8–37.0)
Prior treatment for HCV (no/yes) (%) 359 (69.6)/ 157 (30.4)
Initial dose of PEG-IFN (μg), median (range) 80.0 (40.0–150.0)
Initial dose of ribavirin (mg), median (range) 600 (400–1000)
Pretreatment HCV RNA levels (log10 IU/mL), median (range) 6.1 (5.0–7.7)
Platelet count (×103/μL) 161 (43–352)
Hemoglobin (g/dL) 13.9 (9.7–17.9)
Neutrophil count (/μL) 2489 (578–7480)
Alanine aminotransferase (IU/L) 47 (10–485)
LDL-cholesterol (mg/dL) 99 (25–226)
Total-cholesterol (mg/dL) 171 (29–325)
γ-glutamyl transpeptidase (IU/L) 34.5 (7.0–579)
Alfa fetoprotein (ng/mL) 5.0 (0.8–584)
Fibrosis score (F1/F2/F3/F4) (%) 208(45.9)/139(30.7)/69(15.2)/37(8.2)
Activity score (A1/A2/A3/A4) (%) 258(56.1)/178(38.7)/24(5.2)/0(0)
Genetic polymorphisms of rs8099917 (TT/GG or TG) (%) 288 (72.7)/ 108(27.3)
Amino acid at residue 70 of HCV core (arginine/glutamine or histidine) (%) 242 (67.0)/ 119 (33.0)
Amino acid sequence of ISDR (non-wild-type/wild-type) (%) 110 (26.4)/ 306 (73.6)

BMI, body mass index; HCV, hepatitis C virus; PEG-IFN, peginterferon; ISDR, interferon sensitivity-determining region.

(N = 516).

Toyoda et al.

Toyoda et al. BMC Infectious Diseases 2012 12:324   doi:10.1186/1471-2334-12-324

Open Data